To Evaluate the Safety of Autologous Tumor-infiltrating Lymphocytes(TILs) for the Treatment of Recurrent Ovarian Cancer

Abroad (travel likely)Recruiting

Conditions

Recurrent Ovarian Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Bundang CHA Medical Center, Gyeonggi-do, Bundang-gu, South Korea
Contact: Study coordinator (Miyoung Kim) · a210647@chamc.co.kr · 82-31-780-5306

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy

Ovarian Cancer · Platinum-sensitive Ovarian Cancer · PSOC

Abroad (travel likely)RecruitingPHASE3

Miami, United States · Sarasota, United States

First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer

Advanced Solid Tumors · Breast Cancer Recurrent · Ovarian Cancer

Abroad (travel likely)RecruitingPHASE1

Sarasota, United States · Detroit, United States

SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma

Ovarian Cancer · Cholangiocarcinoma Recurrent · Mesothelioma, Malignant

Abroad (travel likely)RecruitingPHASE1

Tampa, United States · Westwood, United States

Reirradiation and Total Ablative Strategies for Recurrent Gynecologic Cancer

Recurrent Gynecologic Cancer · Recurrent Uterine Cancer · Recurrent Cervical Cancer

Abroad (travel likely)Recruiting

Zamość, Poland